Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)

University Hospital, Caen300 enrolled

Overview

Although lenalidomide (LEN) have proved effective in treating many cancers, few patients receiving LEN may experience rare but life-threatening adverse events such as Acute Lymphoblastic Leukaemia (ALL). Today, data about ALL are scarce. The objective was to investigate reports of ALL adverse events related to LEN in patients with cancer using the World Health Organization (WHO) pharmacovigilance database.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Cancer

Interventions

LenalidomideDRUG

Patients exposed to LEN

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Case reported in the World Health Organization (WHO, also called VigiBase) at the time of the extraction * Patients treated with at least LEN (L04AX04) Exclusion Criteria: -Chronology not compatible between LEN and ALL

Locations (1)

CHU de Caen

Caen, France

Outcomes

Primary Outcomes

ALL reports related to LEN (from WHO database).

Identification of the ALL adverse events related to LEN reported in the World Health Organization (WHO) database of individual safety case reports.

Time frame: From inception to February, 2024

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.